Contact information
+44 (0)1865 617352
+44 (0)1865 617318(PA)
Helen Fanyinka
helen.fanyinka@oncology.ox.ac.uk
Research groups
Colleges
Anne Kiltie
Professor of Experimental Clinical Oncology
- CRUK Senior Clinical Group Leader, Oxford Institute for Radiation Oncology
- Honorary Consultant Clinical Oncologist, Oxford University Hospitals NHS Trust
- Chief Examiner for the MSc in Radiation Biology
Research Summary
I Investigate DNA damage signalling and repair factors in bladder cancer to develop new radiotherapy-based treatments, and to identify markers to select the most suitable treatments for individual patients.
Biography
Anne Kiltie is Professor of Experimental Clinical Oncology and a CRUK Senior Clinical Group Leader at the Oxford Institute for Radiation Oncology. She is also an Honorary Consultant Clinical Oncologist at Oxford University Hospitals NHS Trust.
Between 2001 and 2009 she was a Senior Lecturer / Honorary Consultant Clinical Oncologist at Leeds Institute of Molecular Medicine and St James' University Hospital, Leeds. She was previously a Clinical Research Fellow at the Imperial Cancer Research Fund (ICRF) Clare Hall Laboratories in Hertfordshire. Her clinical training was undertaken at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. She studied Medicine at Sidney Sussex College, Cambridge, and Clinical Medicine at Balliol College, Oxford.
Anne is Chief Examiner for the MSc in Radiation Biology in the Department of Oncology.
GROUP MEMBERS
Ayesha Khan, MSc student
Susan Kilgas, DPhil student
Edward Ottley, Postdoctoral Researcher
Salome Paillas, Postdoctoral Researcher
Robert Pell, Clinical Research Fellow
Gabrielle Price, MRes student
Jia-Ling Ruan, Postdoctoral Researcher
Chee-Kin Then, MRes student
Recent publications
-
Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer
Journal article
KILTIE A. et al, (2020), Journal of Pathology
-
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Journal article
Paillas S. et al, (2020), Int J Radiat Oncol Biol Phys
-
The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
Journal article
KILTIE A. et al, (2020), International Journal of Radiation: Oncology - Biology - Physics
-
The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
Journal article
KILTIE A. et al, (2020), International Journal of Radiation: Oncology - Biology - Physics
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.
Journal article
Witjes JA. et al, (2019), Eur Urol